Shenzhen Neptunus Bioengineering Co Ltd Total Assets
Shenzhen Neptunus Bioengineering Co Ltd total assets. Based on the latest financial reports, Shenzhen Neptunus Bioengineering Co Ltd (000078) holds total assets worth CN¥25.73 Billion CNY (≈ $3.77 Billion USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see 000078 market cap overview for the company's overall valuation and market capitalisation.
Total Assets of Shenzhen Neptunus Bioengineering Co Ltd (1995–2025)
Total assets of Shenzhen Neptunus Bioengineering Co Ltd from 1995 to 2025. This chart illustrates how Shenzhen Neptunus Bioengineering Co Ltd's total assets have evolved over time, based on quarterly financial data. See Shenzhen Neptunus Bioengineering Co Ltd (000078) share price today for real-time trading data and today's change.
Shenzhen Neptunus Bioengineering Co Ltd - Asset Composition Analysis
Shenzhen Neptunus Bioengineering Co Ltd Total Assets Breakdown (December 2025)
Shenzhen Neptunus Bioengineering Co Ltd total assets breakdown as of December 2025. Shenzhen Neptunus Bioengineering Co Ltd's total assets of CN¥25.73 Billion consist of 90.1% current assets and 9.9% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 11.3% |
| Accounts Receivable | CN¥13.20 Billion | 50.1% |
| Inventory | CN¥3.20 Billion | 12.2% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥442.20 Million | 1.7% |
| Goodwill | CN¥241.41 Million | 0.9% |
Asset Composition Trend (1995–2025)
This chart illustrates how Shenzhen Neptunus Bioengineering Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore 000078 net working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Shenzhen Neptunus Bioengineering Co Ltd's current assets represent 90.1% of total assets in 2025, an increase from 57.4% in 1995.
- Cash Position: Cash and equivalents constituted 11.3% of total assets in 2025, down from 13.0% in 1995.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, a decrease from 18.0% in 1995.
- Asset Diversification: The largest asset category is accounts receivable at 50.1% of total assets.
Shenzhen Neptunus Bioengineering Co Ltd Competitors by Total Assets
Key competitors of Shenzhen Neptunus Bioengineering Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276
|
China | CN¥68.33 Billion |
|
Sandoz Group AG
SW:SDZ
|
Switzerland | CHF22.86 Billion |
|
H Lundbeck A/S
CO:HLUN-B
|
Denmark | Dkr54.01 Billion |
|
Changchun High & New Technology Industries Group Inc
SHE:000661
|
China | CN¥30.77 Billion |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566
|
China | CN¥17.01 Billion |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518
|
China | CN¥13.68 Billion |
|
Viyash Scientific Limited
NSE:SEQUENT
|
India | Rs17.26 Billion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥5.11 Billion |
Shenzhen Neptunus Bioengineering Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.00 | 1.02 | 1.04 |
| Quick Ratio | 0.87 | 0.89 | 0.93 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥10.37 Million | CN¥553.93 Million | CN¥1.40 Billion |
Shenzhen Neptunus Bioengineering Co Ltd - Advanced Valuation Insights
This section examines the relationship between Shenzhen Neptunus Bioengineering Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.75 |
| Latest Market Cap to Assets Ratio | 0.02 |
| Asset Growth Rate (YoY) | -8.6% |
| Total Assets | CN¥26.33 Billion |
| Market Capitalization | $492.82 Million USD |
Valuation Analysis
Below Book Valuation: The market values Shenzhen Neptunus Bioengineering Co Ltd's assets below their book value (0.02x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Shenzhen Neptunus Bioengineering Co Ltd's assets decreased by 8.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Shenzhen Neptunus Bioengineering Co Ltd (1995–2025)
The table below shows the annual total assets of Shenzhen Neptunus Bioengineering Co Ltd from 1995 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥26.33 Billion ≈ $3.85 Billion |
-8.56% |
| 2024-12-31 | CN¥28.80 Billion ≈ $4.21 Billion |
-10.85% |
| 2023-12-31 | CN¥32.30 Billion ≈ $4.73 Billion |
-10.89% |
| 2022-12-31 | CN¥36.25 Billion ≈ $5.30 Billion |
-3.59% |
| 2021-12-31 | CN¥37.60 Billion ≈ $5.50 Billion |
-5.33% |
| 2020-12-31 | CN¥39.72 Billion ≈ $5.81 Billion |
-3.52% |
| 2019-12-31 | CN¥41.17 Billion ≈ $6.02 Billion |
+0.10% |
| 2018-12-31 | CN¥41.13 Billion ≈ $6.02 Billion |
+33.25% |
| 2017-12-31 | CN¥30.86 Billion ≈ $4.52 Billion |
+85.24% |
| 2016-12-31 | CN¥16.66 Billion ≈ $2.44 Billion |
+30.55% |
| 2015-12-31 | CN¥12.76 Billion ≈ $1.87 Billion |
+32.50% |
| 2014-12-31 | CN¥9.63 Billion ≈ $1.41 Billion |
+20.11% |
| 2013-12-31 | CN¥8.02 Billion ≈ $1.17 Billion |
+36.77% |
| 2012-12-31 | CN¥5.86 Billion ≈ $858.02 Million |
+21.26% |
| 2011-12-31 | CN¥4.84 Billion ≈ $707.56 Million |
+16.58% |
| 2010-12-31 | CN¥4.15 Billion ≈ $606.95 Million |
+31.06% |
| 2009-12-31 | CN¥3.16 Billion ≈ $463.10 Million |
+13.94% |
| 2008-12-31 | CN¥2.78 Billion ≈ $406.44 Million |
-11.02% |
| 2007-12-31 | CN¥3.12 Billion ≈ $456.79 Million |
-11.38% |
| 2006-12-31 | CN¥3.52 Billion ≈ $515.44 Million |
-11.63% |
| 2005-12-31 | CN¥3.99 Billion ≈ $583.30 Million |
+6.93% |
| 2004-12-31 | CN¥3.73 Billion ≈ $545.50 Million |
-7.49% |
| 2003-12-31 | CN¥4.03 Billion ≈ $589.64 Million |
+17.50% |
| 2002-12-31 | CN¥3.43 Billion ≈ $501.82 Million |
+12.67% |
| 2001-12-31 | CN¥3.04 Billion ≈ $445.38 Million |
+248.92% |
| 2000-12-31 | CN¥872.30 Million ≈ $127.64 Million |
+35.81% |
| 1999-12-31 | CN¥642.28 Million ≈ $93.99 Million |
+179.29% |
| 1998-12-31 | CN¥229.97 Million ≈ $33.65 Million |
+57.92% |
| 1997-12-31 | CN¥145.63 Million ≈ $21.31 Million |
+18.39% |
| 1996-12-31 | CN¥123.00 Million ≈ $18.00 Million |
+49.04% |
| 1995-12-31 | CN¥82.53 Million ≈ $12.08 Million |
-- |
About Shenzhen Neptunus Bioengineering Co Ltd
Shenzhen Neptunus Bioengineering Co., Ltd. engages in the research and development, manufacturing, and distribution of pharmaceuticals in China. The company also provides distribution of medical devices, and other medical supplies, as well as related value-added services. It serves medical institutions, drug retailers, and distributors. Shenzhen Neptunus Bioengineering Co., Ltd. was founded in 19… Read more